colon cancer and egfr inhibitors
Published 6 years ago • 269 plays • Length 0:15Download video MP4
Download video MP3
Similar videos
-
2:01
clarifying the mechanism of egfr inhibition in kras g13d colorectal cancer
-
4:15
egfr in metastatic colon cancer
-
7:32
considerations when selecting an egfr inhibitor in metastatic colorectal cancer
-
16:56
colorectal cancer with acquired resistance to egfr antibodies: how to manage?
-
4:00
optimizing treatment with egfr inhibitors in colorectal cancer
-
22:49
biomarkers for treatment selection in colon cancer
-
1:46
inhibiting braf/egfr/mek for colorectal cancer | oncotarget
-
6:19
clinical development of cetuximab in metastatic colorectal cancer
-
27:07
colon & rectal cancer: what you need to know
-
41:11
food and colon cancer: gut bacteria to genetics
-
8:48
colorectal cancer - overview
-
7:42
egfr-targeted therapy in metastatic colorectal cancer
-
39:45
egfr inhibitors rash management: prevention is key
-
4:56
upfront bevacizumab and cetuximab compared in metastatic colorectal cancer
-
0:42
dr. fakih on anti-angiogenesis versus anti-egfr therapy in colon cancer
-
1:33
acquired resistance to anti-egfr therapy in colorectal cancer
-
32:17
part 2: clinical utility of angiogenesis inhibitors in metastatic colorectal cancer
-
9:00
first- and later-line use of panitumumab in metastatic colorectal cancer
-
20:52
what is the optimal therapy for braf mutant metastatic colorectal cancer?
-
1:31
targeted therapies showing promise in colorectal cancer
-
5:09
egfr therapy as upfront colorectal cancer treatment
-
2:10
anti-egfr therapy for ras wild-type left-sided colorectal cancer